Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · PANACEA BIOTEC LTD · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
PANACEA BIOTEC LTD
NSE: PANACEABIO · BSE: 531349
NSE: PANACEABIO · BSE: 531349
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
PANACEA BIOTEC LTD
StateQ1 FY27 filed
Last close · 21 Sept 2026₹392.75
Market cap₹2.4k cr
TTM P/E · P/B · EV/EBITDA— · 2.90 · 83.1
PANACEA BIOTEC LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 661 | 460 | 559 | 559 | 640 |
| EBITDA (ex other income) | 1,662 | 5 | 16 | 10 | 15 |
| margin % | 251.4 | 1.0 | 2.9 | 1.8 | 2.3 |
| Owners' profit | 1,078 | 0 | (1) | (8) | (5) |
| EPS, as reported (₹) | 175.98 | (5.51) | (0.19) | (1.37) | (0.88) |
| ROE % · ROCE % | 127.4 · 165.9 | (4.0) · 1.8 | (0.2) · 0.5 | (1.0) · (0.4) | (0.9) · (0.1) |
| Debt / equity (x) | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 |
| Cash from operations | (108) | (423) | (0) | (27) | 17 |
| Capex | (13) | (41) | (78) | (50) | (54) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · PANACEA BIOTEC LTD · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| Profit before tax | 5 | 4 | (0) | 7 | (19) | 6 | (1) | 4 |
| Net profit | 5 | 4 | (2) | 4 | (14) | 4 | (1) | 2 |
| EPS (₹) | 0.77 | 0.74 | (0.31) | 0.66 | (2.27) | 0.65 | 0.08 | 0.38 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Vaccines | 410 | 64.1 |
| Formulations | 230 | 35.9 |
| Total, before eliminations | 640 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 2.8 | 3.3 | 74 of 164 | 55% |
| ROCE | (0.8) | 10.8 | 155 of 183 | 15% |
| ROE | (0.9) | 10.4 | 149 of 171 | 13% |
| Debt / Equity | 0.0 | 0.1 | 61 of 171 | 65% |
| EBITDA margin | 6.3 | 17.5 | 137 of 165 | 17% |
| Revenue growth | 19.7 | 16.3 | 70 of 161 | 57% |
| Profit growth | (44.4) | 30.9 | 129 of 158 | 19% |
| Market cap | 2308 | 770 | 75 of 184 | 60% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · PANACEA BIOTEC LTD · 22 September 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 15 Sept 2026 · Reminder to physical shareholders for PAN and KYC updation | compliance | minimal | — | — |
| 8 Sept 2026 · Panacea Biotec publishes 42nd AGM notice and e-voting details in newspapers | compliance | minimal | — | — |
| 7 Sept 2026 · Book closure Sept 25 to Sept 29, 2026 for 42nd AGM | board shareholder meetings | low | — | — |
| 7 Sept 2026 · AGM Notice and Annual Report FY25-26 Weblink Shared with Shareholders | compliance | minimal | — | — |
| 7 Sept 2026 · Notice of 42nd Annual General Meeting on September 29, 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Shares demat update for August 2026 | compliance | minimal | — | — |
| 18 Aug 2026 · Newspaper notice published for 42nd AGM on Sep 29, 2026 | compliance | minimal | — | — |
| 13 Aug 2026 · Q1 FY27 Results: Revenue Up About 20% YoY, Turns Profitable; Going Concern Note | results | high | — | — |
| 12 Aug 2026 · Newspaper notice on special window for physical share transfer and dematerialisation | compliance | minimal | — | — |
| 8 Aug 2026 · Board Meeting on Aug 13 2026 to Approve Q1 FY27 Results | results | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in